Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 22 |
| Active Pipeline (Recruiting Now) | 9 (6) |
| Completed vs Stopped Early | 4 / 4 (18.2%) |
| Median Closed Actual Enrollment | 101 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| London Health Sciences Centre | London, Ontario | 4 |
| Sunnybrook Health Sciences Centre | Toronto, Ontario | 2 |
| McGill University Health Centre | Montreal, Quebec | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06174220 | Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Hamilton Health Sciences Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.